|
시장보고서
상품코드
2038988
바이러스 벡터 및 플라스미드 DNA 제조 시장 : 제품 유형별, 치료 용도별, 최종 제품별, 지역별Viral Vectors And Plasmid DNA Manufacturing Market, By Product Type, By Therapeutic Application, By End Product, By Geography |
||||||
바이러스 벡터 및 플라스미드 DNA 제조 시장은 2026년에 17억 9,860만 달러로 추정되고 있으며, 2033년에 75억 7,110만 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 23%로 성장할 것으로 전망되고 있습니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 17억 9,860만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년 예측 기간의 CAGR : | 23.00% | 2033년 시장 규모 예측 : | 75억 7,110만 달러 |
바이러스 벡터는 유전물질을 표적 세포에 도입하는 데 도움을 주며, 따라서 다양한 치료 분야에서 사용되고 있습니다. 바이러스 벡터는 결핵균, 열대열 말라리아 원충, HIV 등의 병원체나 필로바이러스 등 다양한 생물학적 위협에 대한 백신 개발에 크게 활용될 수 있습니다. 플라스미드 DNA(pDNA)는 유전자 백신 및 유전자 치료의 임상 연구 용도로 주목받고 있습니다. DNA 백신 및 유전자 치료용 신규 생명공학 제품으로서 그 유용성이 점점 더 높아지고 있습니다. pDNA는 치료제로 직접 사용할 수 있을 뿐만 아니라, 일시적 단백질이나 바이러스 벡터 구축체를 생성하기 위한 일시적 형질전환의 원료 등 간접적인 용도로도 폭넓게 활용되고 있습니다. 또한 pDNA는 세포치료제 등 신규 및 개발중인 바이오의약품 및 공정의 생산을 지원하는 마스터 템플릿 제품으로도 사용되고 있습니다.
시장 역학
신규 유전자치료제에 대한 규제 당국의 승인 증가가 유전자치료제 부문의 성장을 촉진할 것으로 예상됩니다. 예를 들어 2017년 9월, GeneOne Life Science, Inc.는 중동호흡기증후군 코로나바이러스(MERS-CoV)에 대한 임상시험용 백신 'GLS-5300'의 I/IIa상 시험에 대한 임상시험계획 신청을 한국 식품의약품안전처(KMFDS)로부터 승인받았습니다. 승인을 받았습니다. 또한 2019년 5월, AveXis Inc.는 2세 이하 소아의 척수성 근위축증(SMA) 치료를 위한 아데노연관바이러스 벡터 기반 유전자 치료제 '졸겐스마(onasemnogene abeparvovec-xioi)'에 대해 미국 식품의약국(FDA)의 승인을 획득했습니다. (FDA)의 승인을 획득했습니다.
본 조사의 주요 특징
- 이 보고서는 각 부문의 잠재적 매출기회를 파악하고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채택한 경쟁 전략에 대한 중요 인사이트를 제공합니다.
- 이 보고서는 다음과 같은 매개 변수를 기반으로 세계의 바이러스 벡터 및 플라스미드 DNA 제조 시장의 주요 기업 개요을 작성했습니다. 기업 개요, 재무 실적, 제품 포트폴리오, 시장에서의 존재감, 유통 전략, 주요 개발, 전략, 미래 계획입니다.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 기술 업그레이드, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것입니다.
- 세계의 바이러스 벡터 및 플라스미드 DNA 제조 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 이 산업의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 바이러스 벡터 및 플라스미드 DNA 제조 시장 분석에 사용되는 다양한 전략 매트릭스를 활용하여 의사결정을 원활하게 할 수 있습니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 범위
제3장 시장 역학, 규제, 동향 분석
제4장 세계의 바이러스 벡터 및 플라스미드 DNA 제조 시장 : 제품 유형별, 2021-2033년
제5장 세계의 바이러스 벡터 및 플라스미드 DNA 제조 시장 : 치료 용도별, 2021-2033년
제6장 세계의 바이러스 벡터 및 플라스미드 DNA 제조 시장 : 최종 제품별, 2021-2033년
제7장 세계의 바이러스 벡터 및 플라스미드 DNA 제조 시장 : 지역별, 2021-2033년
제8장 경쟁 구도
제9장 섹션
KSAViral Vectors And Plasmid DNA Manufacturing Market is estimated to be valued at USD 1,798.6 Mn in 2026 and is expected to reach USD 7,571.1 Mn by 2033, growing at a compound annual growth rate (CAGR) of 23% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 1,798.6 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 23.00% | 2033 Value Projection: | USD 7,571.1 Mn |
Viral vectors aids in transferring genetic material into target cells and therefore, used in various therapeutic areas. Viral vectors can be significantly used in vaccines development against pathogens such as Mycobacterium tuberculosis, Plasmodium falciparum, HIV, and various bio-threat targets such as filoviruses. Plasmid DNA (pDNA) is gaining traction for clinical research applications in genetic vaccination and gene therapy. It is becoming increasingly useful as novel biotechnology product for DNA vaccines and gene medicines. It can be directly used as a therapeutic agent and indirectly used for various applications such as a starting material for transient transfection to produce transient proteins and viral vector constructs. Furthermore, pDNA is used as a master-template product to support production of new and developing biopharmaceutical products and processes such as cell therapies.
Market Dynamics
Increasing approvals by regulatory authorities for novel gene therapies is expected to drive growth of the gene therapy segment. For instance, in September 2017, GeneOne Life Science, Inc., received approval from the South Korean Ministry of Food and Drug Safety (KMFDS) for an Investigational New Drug application for a Phase I/IIa study of its investigational vaccine, GLS-5300, against the Middle East Respiratory Syndrome coronavirus (MERSCoV). Moreover, in May 2019, AveXis Inc. received the U.S. Food and Drug Administration approval for its Zolgensma (onasemnogene abeparvovec-xioi), an adeno-associated virus vector-based gene therapy for the treatment of pinal muscular atrophy (SMA) in children less than two years old.
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global viral vector and plasmid DNA manufacturing market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study include Lonza Group AG, FinVector Vision Therapies, Cobra Biologics and Pharmaceutical Services, Sigma-Aldrich Co. LLC, VGXI, Inc., VIROVEK, SIRION Biotech GmbH, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Sanofi, Cell and Gene Therapy Catapult, Brammer Bio, and MassBiologics.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
- The global viral vector and plasmid DNA manufacturing market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global viral vector and plasmid DNA manufacturing market
Market Segmentation
- By Product Type
- Viral Vector
- Retroviral Vectors
- Adenoviral Vectors
- Lentiviral Vectors
- Adeno-associated Viral Vectors
- Others
- Plasma DNA
- Non-viral DNA Vectors
- By Therapeutic Application
- Cancer
- Inherited Disorders
- Vitrectomy Surgery Devices
- Infectious Diseases
- Others
- By End Product
- DNA Vaccines
- Gene Therapy
- Immunotherapy
- Others
- By Region
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Key Players
- Lonza Group AG
- FinVector Vision Therapies
- Cobra Biologics and Pharmaceutical Services
- Sigma-Aldrich Co. LLC
- VGXI, Inc.
- VIROVEK
- SIRION Biotech GmbH
- FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
- Sanofi
- Cell and Gene Therapy Catapult
- Brammer Bio
- MassBiologics
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Product Type
- Market Snippet, By Therapeutic Application
- Market Snippet, By End Product
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis of DROs
- Comparative Analysis of Different Types of Viral Systems
- Collaborations, Partnerships, And Agreements
- Pipeline Analysis
- New Product Launches
- Investment Opportunities
- Regulatory Scenario
- Strategies For Product Development and Application Pathways
- Brand Analysis
- Cell & Gene Therapy Manufacturing Capacities Globally
- Porter's Analysis
4. Global Viral Vector and Plasmid DNA Manufacturing Market, By Product Type, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Viral Vector
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Retroviral Vectors
- Adenoviral Vectors
- Lentiviral Vectors
- Adeno-associated Viral Vectors
- Others
- Plasma DNA
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Non-Viral DNA Vectors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
5. Global Viral Vector and Plasmid DNA Manufacturing Market, By Therapeutic Application, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Inherited Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Infectious Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
6. Global Viral Vector and Plasmid DNA Manufacturing Market, By End Product, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- DNA Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Gene Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Immunotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
7. Global Viral Vector and Plasmid DNA Manufacturing Market, By Region, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2017-2027
- North America
- Market Size and Forecast, By Product Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Therapeutic Application, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By End Product, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Mn)
- U.S.
- Canada
- Latin America
- Market Size and Forecast, By Product Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Therapeutic Application, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By End Product, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Market Size and Forecast, By Product Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Therapeutic Application, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By End Product, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Mn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Product Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Therapeutic Application, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By End Product, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Market Size and Forecast, By Product Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Therapeutic Application, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By End Product, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Product Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Therapeutic Application, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By End Product, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, (USD Mn)
- South Africa
- Central Africa
- North Africa
8. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Lonza Group AG
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- FinVector Vision Therapies
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Cobra Biologics and Pharmaceutical Services
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Sigma-Aldrich Co. LLC
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- VGXI, Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- VIROVEK
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- SIRION Biotech GmbH
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Sanofi
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Cell and Gene Therapy Catapult
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Brammer Bio
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- MassBiologics
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Analyst Views
- Lonza Group AG
9. Section
- References
- Research Methodology
- About Us and Sales Contact
